Literature DB >> 9181361

Pathology of malignant mesothelioma.

R L Attanoos1, A R Gibbs.   

Abstract

The diagnosis of malignant mesothelioma can pose several problems to the surgical pathologist. First, the morphological appearances of the tumour are known to be diverse with mimicry of a range of both reactive and neoplastic conditions. Second, due to the relative inaccessibility of the serosa, biopsy material is often scanty and fragmentary, producing a plethora of interpretive ambiguities. Third, adjunct techniques such as mucin histochemistry and immunohistochemistry, whilst useful in excluding malignant mesothelioma have little role in confirming the diagnosis. The accurate diagnosis of diffuse malignant mesothelioma is important for two reasons: (1) In relation to prognosis as it has an almost invariable fatal outcome, which contrasts with the other mesothelial neoplasms such as the benign adenomatoid tumour and the borderline malignant tumours, namely the well-differentiated papillary mesothelioma and multicystic mesothelioma; (2) In relation to occupational-related compensation claims following asbestos exposure. This review summarizes the aetiology of asbestos-induced neoplasia, possible mechanisms of tumour development and highlights potential diagnostic pitfalls.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9181361     DOI: 10.1046/j.1365-2559.1997.5460776.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  53 in total

1.  acp. Best practice no 161. Examination of lung specimens.

Authors:  A R Gibbs; R L Attanoos
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

2.  Malignant peritoneal mesothelioma in a pediatric patient mimicking inflammatory bowel disease.

Authors:  Cynthia Oberto; Kathleen B Schwarz; Elias Zambidis; Andrew B Campbell; Charles Paidas; Kenneth Lindyberg; Maria Oliva-Hemker
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

3.  Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis.

Authors:  Marie-Marthe Philippeaux; Jean-Claude Pache; Sophie Dahoun; Marc Barnet; John-Henri Robert; Jacques Mauël; Anastase Spiliopoulos
Journal:  Histochem Cell Biol       Date:  2004-09-15       Impact factor: 4.304

4.  Immunolocalization of caveolin-1 in rat and human mesothelium.

Authors:  Christopher J von Ruhland; Lee Campbell; Mark Gumbleton; Bharat Jasani; Geoffrey R Newman
Journal:  J Histochem Cytochem       Date:  2004-11       Impact factor: 2.479

Review 5.  Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.

Authors:  Alfonso García-Fadrique; Akash Mehta; Faheez Mohamed; Sanjeev Dayal; Tom Cecil; Brendan J Moran
Journal:  J Gastrointest Oncol       Date:  2017-10

6.  Pleural fluid findings as prognostic factors for malignant pleural mesothelioma.

Authors:  Tanseli Efeoglu Gonlugur; Ugur Gonlugur
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

7.  Pathology of mesothelioma.

Authors:  Kouki Inai
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

Review 8.  The legacy of the F344 rat as a cancer bioassay model (a retrospective summary of three common F344 rat neoplasms).

Authors:  Robert R Maronpot; Abraham Nyska; Jennifer E Foreman; Yuval Ramot
Journal:  Crit Rev Toxicol       Date:  2016-06-09       Impact factor: 5.635

Review 9.  Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.

Authors:  Terence C Chua; Tristan D Yan; David L Morris
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

Review 10.  Late cutaneous metastases to the face from malignant pleural mesothelioma: a case report and review of the literature.

Authors:  Alaaeldeen M Elbahaie; Dia E Kamel; Julia Lawrence; Neville G Davidson
Journal:  World J Surg Oncol       Date:  2009-11-09       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.